Holen Sie sich die Stockscreener-App
54.86
1.29%
0.70
Handel nachbörslich:
55.54
0.68
+1.24%
Schlusskurs vom Vortag:
$54.16
Offen:
$54.29
24-Stunden-Volumen:
2.05M
Relative Volume:
0.98
Marktkapitalisierung:
$10.53B
Einnahmen:
$2.95B
Nettoeinkommen (Verlust:
$523.88M
KGV:
20.39
EPS:
2.69
Netto-Cashflow:
$620.18M
1W Leistung:
+2.03%
1M Leistung:
-5.85%
6M Leistung:
-19.25%
1J Leistung:
-21.74%
1-Tages-Spanne:
$54.26
$55.75
1-Wochen-Bereich:
$52.48
$55.75
52-Wochen-Spanne:
$52.48
$73.51
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Firmenname
Biomarin Pharmaceutical Inc
Sektor
Branche
Telefon
(415) 506-6700
Adresse
105 DIGITAL DRIVE, NOVATO, CA
Vergleichen Sie BMRN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
54.86 | 10.40B | 2.95B | 523.88M | 620.18M | 2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
404.21 | 100.41B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
599.94 | 59.59B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.65 | 59.77B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
767.33 | 45.14B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
335.16 | 37.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-08 | Eingeleitet | H.C. Wainwright | Neutral |
| 2025-09-03 | Eingeleitet | Raymond James | Outperform |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-02-24 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-30 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-08-20 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | Eingeleitet | Evercore ISI | Outperform |
| 2023-11-15 | Eingeleitet | Wells Fargo | Overweight |
| 2023-10-23 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | Eingeleitet | Raymond James | Mkt Perform |
| 2023-09-18 | Eingeleitet | UBS | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Perform |
| 2023-07-05 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-03-21 | Eingeleitet | Bernstein | Underperform |
| 2023-02-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-02-21 | Eingeleitet | Citigroup | Neutral |
| 2023-01-30 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Hold |
| 2022-10-31 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-13 | Fortgesetzt | Wedbush | Neutral |
| 2022-04-25 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | Fortgesetzt | Jefferies | Buy |
| 2021-09-09 | Hochstufung | Stifel | Hold → Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-04 | Fortgesetzt | Guggenheim | Buy |
| 2021-03-01 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-08-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-08-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2020-08-19 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | Herabstufung | Stifel | Buy → Hold |
| 2020-07-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | Bestätigt | Citigroup | Buy |
| 2020-01-28 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-01-27 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-01-24 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-05-23 | Fortgesetzt | Citigroup | Buy |
| 2019-04-09 | Fortgesetzt | Raymond James | Outperform |
| 2019-01-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-08-07 | Bestätigt | Stifel | Buy |
| 2018-08-03 | Bestätigt | Stifel | Buy |
Alle ansehen
Biomarin Pharmaceutical Inc Aktie (BMRN) Neueste Nachrichten
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock - Yahoo Finance
Take Care Before Diving Into The Deep End On BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - 富途牛牛
Pompe Disease Market Analysis Report 2025-2035: Enzyme Replacement Therapies and Approvals of Myozyme and Nexviazyme Drive Steady Growth - GlobeNewswire Inc.
How institutional ownership impacts BioMarin Pharmaceutical Inc. stockEarnings Risk Summary & Real-Time Volume Analysis Alerts - newser.com
BioMarin: Valuation, Growth, And The Pipeline May Outweigh TransCon Competition And Regulatory Risks - Seeking Alpha
Tealwood Asset Management Inc. Increases Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Raymond James Maintains a Buy Rating on BioMarin Pharmaceutical (BMRN), Sets a $85 PT - Yahoo
Real time alert setup for BioMarin Pharmaceutical Inc. performanceCPI Data & Fast Moving Trade Plans - newser.com
Can BioMarin Pharmaceutical Inc. stock reach $100 price targetEarnings Trend Report & Precise Trade Entry Recommendations - newser.com
How BioMarin Pharmaceutical Inc. stock performs in stagflationRate Cut & Daily Profit Maximizing Trade Tips - newser.com
BioMarin Pharmaceutical Inc. (BMRN) Stock Analysis: Exploring a Compelling 78% Upside Potential - DirectorsTalk Interviews
Is BioMarin Pharmaceutical Inc a good long term investmentRetail Investor Activity & Optimize Entry & Exit With Smart Signals - earlytimes.in
What analysts say about BioMarin Pharmaceutical Inc stockInsider Selling Patterns & Budget Friendly Trading Strategies - earlytimes.in
Is BioMarin Pharmaceutical Inc BM8 a good long term investmentPrice Volatility Patterns & Superior Wealth Growth - earlytimes.in
BioMarin Pharmaceutical Hits New 52-Week Low at $52.48 - Markets Mojo
Is BioMarin Pharmaceutical Inc. stock a safe buy before earningsPortfolio Growth Summary & Weekly Top Gainers Alerts - newser.com
Wealth Enhancement Advisory Services LLC Raises Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Biomarin Pharmaceutical stock hits 52-week low at $52.93 By Investing.com - Investing.com Nigeria
Perpetual Ltd Acquires New Stake in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Biomarin Pharmaceutical stock hits 52-week low at $52.93 - Investing.com India
BioMarin Pharmaceutical (NASDAQ:BMRN) Reaches New 12-Month LowTime to Sell? - MarketBeat
BioMarin Pharmaceutical Inc. $BMRN Shares Acquired by Covea Finance - MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Short Interest Update - MarketBeat
Strs Ohio Buys Shares of 16,000 BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Pharmaceutical Inc.(NasdaqGS: BMRN) dropped from FTSE All-World Index - MarketScreener
Assenagon Asset Management S.A. Purchases 230,362 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Acadian Asset Management LLC Reduces Stake in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Aug Movers: Why is BioMarin Pharmaceutical Inc. stock going upOil Prices & Community Trade Idea Sharing - خودرو بانک
BioMarin Pharmaceutical Inc. $BMRN Shares Sold by Intech Investment Management LLC - MarketBeat
Performance Recap: Should I invest in BioMarin Pharmaceutical Inc before earningsJuly 2025 Decliners & Expert Verified Movement Alerts - خودرو بانک
Wesbanco Bank Inc. Purchases 19,000 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term - sharewise.com
Aug PreEarnings: What is the target price for BioMarin Pharmaceutical Inc stockBond Market & Fast Gain Stock Trading Tips - خودرو بانک
Aug Action: Is BioMarin Pharmaceutical Inc. stock forming a cup and handleWeekly Trend Summary & Stepwise Swing Trade Plans - khodrobank.com
12 Best Beginner Stocks to Buy According to Analysts - Insider Monkey
Ideas Watch: How does BioMarin Pharmaceutical Inc score in quality rankingsEarnings Performance Report & Real-Time Buy Signal Notifications - خودرو بانک
Levels Update: Can BioMarin Pharmaceutical Inc. scale operations efficientlyQuarterly Trade Summary & Consistent Growth Equity Picks - khodrobank.com
BioMarin Pharmaceutical Inc.’s (BMRN) Phenylketonuria Candidate Drug Impresses in Phase 3 Trials - Insider Monkey
November 21st Options Now Available For BioMarin Pharmaceutical (BMRN) - Nasdaq
Leerink Partners Reiterates a Buy Rating on BioMarin Pharmaceutical (BMRN), Sets a PT of $105 - MSN
BioMarin Pharmaceutical Inc. $BMRN Shares Bought by Goldman Sachs Group Inc. - MarketBeat
UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Has $75.28 Million Stake in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BMO Capital Reiterates a Buy on BioMarin Pharmaceutical (BMRN) - MSN
Finanzdaten der Biomarin Pharmaceutical Inc-Aktie (BMRN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.95%
1.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):